Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study
Authors' conclusion
The Mylife Dose app does not improve glycemic control or QoL significantly but offers convenience for patients with T1D. In contrast, HCLSs provide significant metabolic and QoL benefits
Study context
- Population
- Adults with T1D using isCGM and multiple daily injections (MDI), transitioning to continuous subcutaneous insulin infusion (CSII) with the Mylife Dose app and later to an HCL system88.1% completed
- Participants
- 135 adults
- Comparison
- CSII with Mylife Dose app, then HCL system, after MDI
- Outcome
- Glycemic control (HbA1c, TIR) and QoL
Methodological detailsmulticenter, 10-month, descriptive, Adherence high: 88.1% completed the study
- Multicenter
- 10-month
- Descriptive
- Adherence high: 88.1% completed the study
Main finding
As reported in the abstract
HbA1c with HCLS
6.7%
TIR with HCLS
73.1%
Patients achieving HbA1c <7% with HCLS
over 70%
Further findings
Insulin requirements
- Increased slightly with HCLS, primarily due to basal insulin
Original publication
Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study. Diabetes Technol Ther. Published 29 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →